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1. Introduction 
Statins are common lipid lowering agents to reduce elevation of cholesterol or as 
prophylaxis against other cardiac diseases. It estimated that 62.5% to 91.7% of dyslipidemic 
patients in United State of America are using statins1 These agents widely used among 
cardiovascular patients in Malaysia2. In other countries, for example in UK, it has found that 
most patients who use statins are older than 35 years old and more of them are males 
(56%)3. In Canada, about 90% of cardiac patients are using statin, while in US, at least one 
third of all cardiac patients are using statins4. About 60% of American patients who older 
than 60 years old are using statin5. Thus, high number of users contributed to increase the 
risk of adverse drug reactions (ADRs).  
The Food and Drug Administration (FDA) has determined that common statin-associated 
ADRs are fatigue, muscle pain, joints pain, back pain, visual disturbance and insomnia6,7. 
Previous studies have examined the incidence of these ADRs, and their results showed that 
more than half of the reported cases of muscle pain were related to statin use8,9. Clearfield et 
al found that fatigue, muscle pain, and bone pain were common and frequent ADRs in UK, 
and related to atorvastatin and rosuvastatin use10. Other studies exploring ADRs in patients 
using atorvastatin and lovastatin in the US found that muscle pain and fatigue were the 
most common statin-related ADRs11. The UK Committee on Safety of Medicines, as well as 
other studies, have reported that these symptoms should consider as early signs for more 
serious ADRs8,12-15. However, from our knowledge, no data available on the common ADRs 
statin-related and their predictors for Asian patients. Only a few studies (not related with 
Asian patients) have found out the predictors of the statin-related ADRs8,9,10,16,17. As health 
care professional, they should find methods to ensure patients not only receive effective 
medication but also feel comfortable with the therapy. Thus, the objectives of this study was 
to determine the common statin-related ADRs and their predictors in one of the referral 
hospital in Malaysia (one of country in South East Asia). 
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2. Method 
Cross-sectional with convenient sampling study conducted for volunteer outpatients from 
the cardiac clinic of Penang Hospital in Pulau Pinang State of Malaysia. Study protocol was 
approved by Clinical Research Committee of Penang General Hospital, and signed consent 
forms were obtained from all participants. The patients included in this study were at least 
18 years old and voluntarily to participate in this study. They have to used statins and could 
understand Malay Language (the National Language of Malaysia) or English Language, 
since Malaysia is a multiracial country. Patients who allergies to statin, pregnant or lactating 
women, or changing in types or dosage of statin used were excluded from this study. These 
types of patients excluded because their conditions may affected outcomes of the study. The 
study period was 5 months, and 1900 patients presented in the cardiac clinic within this 
study period. Depending on inclusion and exclusion criteria, 500 patients voluntarily agreed 
to participate in this study. A validated questionnaire form (Cronbach’s alpha is 0.853) were 
used for reporting of ADRs. The patients were asked whether they have experience of 
common statin-related ADRs while they were on statin therapy and give their answers on 
the self-report questionnaire forms. This questionnaire form has some questions on 
demographic data and undesired symptoms that patients had during statin therapy. There 
were 27 ADRs of statin listed in the questionnaire form. They were required to tick yes or no 
on these listed ADRs. They can tick more than one ADR. In order to ensure these ADRs 
really related with statin therapy these patients had to indicate in the questionnaire form 
that these ADRs occurred while they were receiving statin therapy and these symptoms 
should continuously occurred at least for 3 months.  
3. Statistics 
Statistical Package for Social Science software (SPSS) version 18 used to analyze the data for 
this study. Odd ratio and Chi-square and logistic regression tests were used to ensure these 
ADRs were related with stain therapy and to determine their predictors. The results with p 
value less than 0.05 was considered statistically significant.  
4. Results 
Male patients (70%) were the more frequent users of statins, with mean age 60±10 years. The 
most frequent race that used statins was Chinese (37.6%), followed by Malays (34.4%), 
Indians (26.6%) and foreigners (1.4%). Small numbers of patients were cigarette smoker 
(12%) and alcohol consumers (9%).  
Higher number of patients had dyslipidemia with primary type (51.5%) based on the 
Friedewald et al18 and Stone et al19 classifications. For primary subtypes of dyslipidemia, the 
most common subtype was IIa (50.6%), while common subtype of secondary dyslipidemia 
was diabetes (86.3%). The common type of statin used was lovastatin (81%), followed by 
simvastatin (9.4%) and atorvastatin (8%). The low dose (20 mg) of statin was the common 
prescribed to these patients. The mean duration of statin therapy was 3.5 years and the most 
frequent range of duration was 1-5 years (52.5%), as shown in Table 1.  
Statistical regression analysis was used to exclude symptoms related to other medications 
and diseases. It found only few symptoms from 27 ADRs that correlated significantly with 
statins were; fatigue (59.4%), muscle pain (53.6%), joint pain (53.4%), back pain (47.8%), 
insomnia (44.8%) and visual disturbances (44.2%).  
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Demographics Variables  No (%) 
Gender  Male  351 (70%) 
Female  149 (30%) 
Race  Malay  172 (34.4%) 
Chinese  188 (37.6%) 
Indian  133 (26.6%) 
Foreign 7 (1.4%) 
Age (mean 60±10)year 28-50 year 94 (19%) 
51-65 year 258 (51%) 
66-92 year 148 (30%) 
Smoke  Yes  59 (12%) 
No  441 (88%) 
Alcohol consuming  Yes  47 (9%)  
No  453 (91%) 
Dyslipidiemia type  Primary  247 (51.5%) 
Secondary  233 (48.5%) 
Primary dyslipidemia 
subtype  
I 13 (5.3%) 
IIa 125 (50.6%) 
IIb 59 (23.9%) 
III 7 (2.8%) 
IV 32 (13%) 
V 11 (4.5%) 
Secondary 
dyslipidemia subtype 
Renal  17 (7.3%) 
Diabetes  201 (86.3%) 
Nephrotic syndrome  1 (0.4%) 
Liver  1 (0.4%) 
Drugs 2 (0.9%) 
Hypothyroidism  11 (4.7%) 
Type of statin Atorvastatin  40 (8%) 
Simvastatin  47 (9.4%) 
Lovastatin  405 (81%) 
others 8 (1.6) 
Combination therapy  Yes  35 (7%) 
No  465 (93%) 
Duration of therapy 
Mean (3.5±3.0) year 
3months or less 16 (3.2%) 
3months -1 year 133 (26.7%) 
 1-5 years 262 (52.5%) 
5-20 years 89 (17.6%) 
Table 1. Demographic data of 500 cardiac outpatients in Penang General Hospital 
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Predictors  ADRs (percentage,  P value, OR, CI) 
Fatigue 
Muscle 
pain 
Joint pain Back pain Insomnia 
Visual 
disturb-
ances 
Gender 
(female) 
NS NS 61.74%, 
P=0.007, 
OR= 
1.864, CI= 
1.18-2.94 
56.38%, 
P= 0.02, 
OR= 1.73, 
CI= 1.09-
2.75 
NS NS 
Race 
(Indian) 
68.42%, 
P=0.027, 
OR= 1.81, 
CI= 2.14-
2.75) 
66.92%, 
P= 0.016, 
OR=1.94, 
CI= 1.13-
3.32) 
NS 62.4%, 
P=0.007, 
OR= 2.18, 
CI= 1.23-
3.72 
NS 49.62%, 
P=0.016, 
OR= 1.74, 
CI= 1.11-
2.73) 
Smokers NS NS NS NS NS NS 
Alcoholic 76.60%, 
P= 0.011, 
OR= 3.0 
CI= 1.29-
7.01) 
NS NS 65.96%, 
P= 0.003, 
OR= 3.58, 
CI= 1.53-
8.38 
59.57%, 
P=0.006, 
OR= 2.89, 
CI= 1.36-
6.15 
NS 
Age NS NS NS NS NS NS 
Duration 
More than 
5 years 
53.41%, 
P=0.036, 
OR= 1.83, 
CI= 1.04-
3.23) 
60.23%, 
P=0.016, 
OR=1.96, 
CI= 1.133-
3.39 
NS 57.95%, 
P=0.001, 
OR=2.61, 
CI= 1.50-
4.54) 
NS NS 
Primary 
subtypes 
(type IIb) 
NS NS NS 33.90%, 
P= 0.014, 
OR= 2.50, 
CI= 1.21-
5.19) 
NS NS 
Secondary 
subtypes 
(renal 
disease) 
NS NS NS NS 64.71%, 
P= 0.33, 
OR= 3.7, 
CI= 1.11-
12.33 
NS 
Statin types NS NS NS NS NS NS 
Atorvastatin 
doses 
(20mg) 
NS NS NS NS NS NS 
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Simvastatin 
dose 
(40mg) 
NS NS NS NS NS NS 
Lovastatin 
doses 
(60mg) 
72.73%,  
P=0.003, 
OR= 1.90, 
CI= 1.25-
2.89) 
NS NS NS NS NS 
Combination 
therapy 
NS NS NS NS NS NS 
NS= no significant  
Table 2. Relationship between statin related ADRs and predictors 
In term of predictor, females significantly had joint pain (61.74%, OR = 1.864) and back pain 
(56.38%, OR = 1.73). However, there was no significant relation between gender with 
fatigue, muscle pain, insomnia and visual disturbance. Indian patients had significantly 
higher incidence of fatigue (68.42%, OR= 1.81), muscle pain (66.92%, OR =1.94), back pain 
(62.4 %, OR = 2.18), and visual disturbances (49.62 %, OR = 1.738) when compared to other 
races. No significant relationship found between smoking and statin related-ADRs. Patients 
who consumed alcohol significantly had fatigue (76.6%, OR = 3.0), back pain (65.96%, OR = 
3.584) and insomnia (59.57%, OR = 2.893). Age was without effect on incidence of statin 
related-ADRs. Patients used statins for more than 5 years significantly had fatigue (53.41%, 
OR = 1.83) and muscle pain (60.23%, OR =1.958), as shown in Table 2. 
For secondary dyslipidemia types, renal induced dyslipidemia significantly caused higher 
incidence of insomnia when compared to the other secondary subtypes (64.71%, OR = 3.7). 
For subtypes of primary dyslipidemia, subtype IIb patients had significantly back pain 
(81.82%, OR = 2.5).  
No significant relationship found between statin related-ADRs and statin types, the patients 
used simvastatin had a higher incidence of fatigue (65.96%), joint pain (57.45%), back pain 
(55.32%) and visual disturbance (53.19%). Patients used lovastatin had insomnia (45.68%), 
while patients used atorvastatin had higher incidence of muscle pain (52.17%). No 
significant relationship found between doses of statins and other ADRs except for lovastatin 
dose. Patients used 60 mg dose of lovastatin had significantly fatigue than patients used 
lower doses (72.73%, OR = 1.904). No significant relation found between the combination 
with other lipid lowering agents and incidence of ADRs (as shown in Table 2).  
5. Discussion 
After two decades of statin marketing, significant incidences of adverse drug reactions still 
presented during therapy. Number of studies of medications' ADRs always increased after 
first years of launching, but it found this matter is different with type of statin used20. Most 
of previous studies focused on serious ADRs of statin like muscle toxicity, elevation of liver 
enzymes, renal toxicity and polyneuropathy21,22. Although serious ADRs caused mortalities 
and death to patients, but their incidences are lower than other adverse reactions of statin 
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symptomatic related ADRs. Kashani A. et al. 23 found that incidences of patients 
discontinued their therapy because of symptomatic ADRs of statin (5.6%) were higher than 
patients had rhabdomyolysis (0.2%), hepatotoxicity (1.4%), and creatine kinase (CK) 
elevations (0.9%). Therefore, self-reporting of ADRs are useful to determine and predict the 
toxicities induced by medication24. There are few studies done on the common statin-related 
ADRs that use patient self-report. There was a previous study that focused on the common 
ADRs during statin therapy and their predictors in cardiac outpatients. They reported the 
use of a self-report questionnaire form is suitable approach to assess the common undesired 
symptoms found during statin therapy25. In the real-life practice, doctors are more focusing 
on dyslipidemia and its complications than statin-related ADRs of their patients. 
Furthermore, self-report approach allows the patients to express directly their unwanted 
problems associated with statin therapy. In addition, patients sometimes feel uncomfortable 
or inappropriate telling their doctor about these undesired symptoms of statin26,27. The 
finding in this study showed a higher incidence of fatigue and muscle pain in this cardiac 
outpatients setting, which consistent with previous studies8,10.  
In this study, females reported having back and joint pain significantly more than males did. 
Female patients are more sensitive to ADRs than males possibly because of pharmacokinetic 
and pharmacodynamic differences between genders28. Not all ADRs of statin related to 
gender, this finding supported by FDA, Bayer reports and previous studies29-32. When 
compared to other races, Indian patients had significantly higher incidence of some common 
ADRs (fatigue, muscle pain, back pain and visual disturbance). This is because genetics also 
has contributed in adverse drug reactions23. This result was supported by FDA reports in 
which ADRs were different among races7. Cigarette smokers had increased incidence of 
these ADRs than nonsmokers, however this finding was not statistically significant. Alcohol 
consumers had significant problems with fatigue, back pain and insomnia, and increased 
incidence of ADRs in general30. This is because alcohol causes mitochondrial dysfunction, 
which would increase the risk of muscle disorders caused by statins33. There was no 
relationship between age and ADRs, as shown in Table 2, which supported by Kucukarslan 
et al study34. There was a relationship between duration of statin used and ADRs in 
previous studies29,35,36. Their finding were consistent with this present finding, where the 
duration of statin therapy has related to fatigue, muscle pain and back pain.  
Based on our knowledge, no previous studies reported the relationship between 
dyslipidemia types and the common ADRs. Significant relationship was found in this study 
between dyslipidemia type (primary and secondary) and common ADRs. Patients who had 
secondary dyslipidemia type had increase frequency of insomnia than with primary type. 
Patients with subtype IIb and renal induced dyslipidemia were significantly more likely to 
have back pain and insomnia than other subtypes.  
Although statins differ in their pharmacokinetic properties37,38, there is no significant 
relationship found between statin types and common ADRs. However, simvastatin was 
more likely to cause fatigue, joint pain, back pain and visual disturbance than other statins. 
Although there is no significant relation found between atorvastatin and common ADRs. 
Atorvastatin found to cause muscle pain more often than other statin types, this finding also 
proved by Clearfield et al. and Golomb et al. 10,11. Patients on lovastatin therapy had higher 
incidence of insomnia than other types of statin. Higher doses for all types of statins have 
resulted in a higher incidence of ADRs. The higher dose of lovastatin (60 mg) significantly 
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associated with fatigue. The dose of statins used did not have significant relationship with 
other symptoms of common ADRs. This result is consistent with other studies12,39. Finally, 
there was no significant relationship between combination therapy and ADRs. This 
relationship could not be seen possibly due to small number of patients receiving more than 
one type of antilipidemic agent. 
The finding of this study showed that significant number of patients feel undesired effects of 
statin therapy and their predictors. Adjustment or manipulating of these preventable 
predictors such as to change type of statin used, reduce dose and duration are 
recommended to the prescribers. For example, based on the odd ratio, fatigue was the 
highest for patients who are alcohol consumers, followed by lovastatin dosage, duration and 
race. Therefore, steps needed to reduce the incidence of fatigue by avoiding or reducing the 
preventable predictors that related to these common ADRs like cessation of alcohol and 
changing in type or dose of statin used.  
6. Conclusion 
This paper explained that significant number of cardiac outpatients were experienced 
common ADRs related-statin through self-report approach and their predictors. Common 
ADRs of statin were fatigue, muscle pain, joint pain, back pain, insomnia and visual 
disturbances. The main predictors or contributing factors of common statin-related ADRs 
were gender, race, alcohol consumption, duration of statin used, renal induced-secondary 
dyslipidemia, subtype IIb of primary dyslipidemia and lovastatin dose. These predictors are 
useful in clinical practice to determine the likelihood of ADRs and to manage the common 
ADRs of statin in cardiac outpatients. Finding from this study was suggested appropriate 
dose and type of statin use and also adjustment of the preventable predictors may minimize 
common ADRs of statin in cardiac outpatients. Appropriate prospective study design with 
multicenter sites recommended determining the actual effects of these preventable 
predictors on common ADRs of statin. 
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